Phase II, randomized, multicenter, comparative study of peginterferon–α–2a (40 kD) (Pegasys®) versus interferon α-2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Leukemia & Lymphoma

• Publication date

  2007-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/10428190601175393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Generalisability in economic evaluation studies in healthcare: a review and case studies.

  2004cited by this paper
• Optimizing treatment of chronic myeloid leukemia: a rational approach.

  2004cited by this paper
• Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.

  2004cited by this paper
• Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study

  2004cited by this paper
• Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome‐positive chronic myelogenous leukemia in the chronic phase

  2003cited by this paper
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cited by this paper
• Pharmacokinetics of Peginterferons

  2003cited by this paper
• Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis

  2003cited by this paper
• Recent advancements in the treatment of chronic myelogenous leukemia.

  2002cited by this paper
• Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma

  2002cited by this paper
• Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.

  2002cited by this paper
• Immune-mediated complications during interferon alpha therapy in chronic myelogenous leukemia.

  2002cited by this paper
• Current therapy of chronic myelogenous leukemia.

  2002cited by this paper
• Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.

  2001cited by this paper
• Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.

  2001cited by this paper
• Chronic myelogenous leukemia in chronic phase

  2001cited by this paper
• Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

  2001cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C.

  2000cited by this paper
• An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.

  1999cited by this paper
• Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy.

  1998cited by this paper
• A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

  1998cited by this paper
• Chronic myelogenous leukemia: a review.

  1996cited by this paper
• Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia.

  1995cited by this paper
• Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon- Therapy

  1995cited by this paper
• Chronic myelocytic leukemia patients achieving complete cytogenetic conversion under interferon alpha therapy: minimal residual disease follow-up.

  1995cited by this paper
• Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.

  1994cited by this paper
• Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.

  1993cited by this paper
• Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.

  1993cited by this paper
• Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration.

  1988cited by this paper
• Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.

  1986cited by this paper

• Strategies for Modifying Adenoviral Vectors for Gene Therapy

  2024cites this paper
• Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation

  2021cites this paper
• A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.

  2021cites this paper
• Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia

  2021cites this paper
• Bispecific Antibody (HER2 × mPEG) Enhances Anti-Cancer Effects by Precise Targeting and Accumulation of mPEGylated Liposomes.

  2020cites this paper
• Colorectal Cancer Immunotherapy: Options and Strategies

  2020cites this paper
• A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)—AGMT_CML 1

  2020cites this paper
• Thrombocytosis

  2019cites this paper
• Organic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myeloid Leukemia

  2019cites this paper
• Polyethylene Glycol Nanoparticles as Promising Tools for Anticancer Therapeutics

  2019cites this paper
• Can increased immunogenicity in chronic myeloid leukemia improve outcomes?

  2019cites this paper
• Interferon beta induces apoptosis in nasopharyngeal carcinoma cells via the TRAIL-signaling pathway

  2018cites this paper
• Neurological Complications of Immune-Based Therapies

  2018cites this paper
• Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia

  2018cites this paper
• Dose‐escalation study evaluating pegylated interferon alpha‐2a in patients with cutaneous T‐cell lymphoma

  2017cites this paper
• Pregnancy: part of life in chronic myelogenous leukemia

  2017cites this paper
• Progress in the Discovery of BCR-ABL Kinase Inhibitors for the Treatment of Leukemia

  2017cites this paper
• PEGylation in anti-cancer therapy: An overview

  2016cites this paper
• Beyond tyrosine kinase inhibitors: Combinations and other agents.

  2016cites this paper
• The interferon-alpha revival in CML

  2015cites this paper
• Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS

  2015cites this paper
• Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.

  2015cites this paper
• Adenovirus-Vector-Mediated Gene Delivery: Barriers and Chemical Vector Modifications

  2015cites this paper
• Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era

  2014cites this paper
• Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis

  2013cites this paper
• Long-term effect of interferon-α combined with homoharringtonine on chronic myelogenous leukemia in chronic phase

  2013cites this paper
• Chapter 16 – Comprehensive Immunomonitoring to Guide the Development of Immunotherapeutic Products for Cancer

  2013cites this paper
• Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia

  2013cites this paper
• Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia

  2013cites this paper
• Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

  2012cites this paper
• Interferon-α/β receptor as a prognostic marker in osteosarcoma.

  2011cites this paper
• Monitoring response and resistance to treatment in chronic myeloid leukemia.

  2011cites this paper
• RAFT-synthesized graft copolymers that enhance pH-dependent membrane destabilization and protein circulation times.

  2011cites this paper
• Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

  2011cites this paper
• Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.

  2011cites this paper
• Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.

  2011cites this paper
• Primary Myelofibrosis (PMF) [Previously Chronic Idiopathic Myelofibrosid (CIMF), Myelofibrosis with Myeloid Metaplasia (MMM), Agnogenic Myeloid Metaplasia (AMM)]

  2010cites this paper
• Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

  2010cites this paper
• Chronic Myelogenous LeukemiaPractice Guidelines in Oncology TM

  2009cites this paper
• Interferon in chronic myeloid leukaemia: past and future.

  2009cites this paper
• PEG conjugates in clinical development or use as anticancer agents: an overview.

  2009cites this paper
• Identifying and treating imatinib failure in chronic myelogenous leukemia: a practical review of treatment guidelines and available agents

  2009cites this paper
• Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

  2009cites this paper
• Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide.

  2008cites this paper
• Combined treatment with pegylated interferon–α‐2a and dacarbazine in patients with advanced metastatic melanoma

  2008cites this paper
• PEG‐IFN‐α‐2b therapy in BCR‐ABL–negative myeloproliferative disorders

  2007cites this paper
• Chronic myeloid leukaemia.

  2007cites this paper
• [Side effects during interferon-alpha therapy of hepatitis C with special consideration of thyroid dysfunction].

  2007cites this paper
• Is there still a role for interferon-alpha for newly diagnosed chronic myeloid leukemia in chronic phase?

  2007cites this paper